Why the study?
Because biological valve longevity and homograft availability are limited for treating pulmonary regurgitation after relief of RVOT obstruction, intermediate-term results of pulmonary valve reconstruction were evaluated.
Does pulmonary valve reconstruction provide acceptable intermediate-term freedom from valve replacement in patients with severe acquired pulmonary regurgitation after treated congenital heart disease?
Does pulmonary valve reconstruction provide acceptable intermediate-term freedom from valve replacement in patients with severe acquired pulmonary regurgitation after treated congenital heart disease?
Pulmonary valve reconstruction offers acceptable intermediate-term results and may delay the need for pulmonary valve replacement in patients with treated congenital heart disease and severe pulmonary regurgitation.
PVr may serve as a valve-sparing option after transannular patch; leaves open durability and generalizability pending larger prospective data.
OBJECTIVES: Pulmonary valve regurgitation is a common problem after relief of right ventricular outflow tract (RVOT) obstruction with a transannular patch. Pulmonary valve replacement with a homograft or xenograft is the routine treatment. Longevity of biological valves and the availability of homografts are limited. Alternatives to restore RVOT competence are evaluated. The goal of this study was to present intermediate-term results for pulmonary valve reconstruction (PVr) in patients with severe regurgitation. METHODS: PVr was performed in 24 patients (August 2006‒July 2018). We analysed perioperative data, pre- and postoperative cardiac magnetic resonance (CMR) imaging studies, freedom from valve replacement and risk factors for pulmonary valve dysfunction. RESULTS: The underlying diagnoses were tetralogy of Fallot (n = 18, 75%), pulmonary stenosis (n = 5, 20.8%) and the double outlet right ventricle post banding procedure (n = 1, 4.2%). The median age was 21.5 (14.8-23.7) years. Main (n = 9, 37.5%) and branch pulmonary artery procedures (n = 6, 25%) and surgery of the RVOT (n = 16, 30.2%) were often part of the reconstruction. The median follow-up after the operation was 8.0 (4.7-9.7) years. Freedom from valve failure was 96% at 2 and 90% at 5 years. The mean longevity of the reconstructive surgery was 9.9 years (95% confidence interval: 8.8-11.1 years). CMR before and 6 months after surgery showed a reduction in the regurgitation fraction [41% (33-55) vs 20% (18-27) P = 0.00] and of the indexed right ventricular end-diastolic volume [156 ml/m2 (149-175) vs 116 ml/m2 (100-143), P = 0.004]. Peak velocity across the pulmonary valve (determined by CMR) half a year after surgery was 2.0, unchanged. CONCLUSIONS: PVr can be achieved with acceptable intermediate-term results and may delay pulmonary valve replacement.
No takes yet. Share an insight, caveat, or question.
Jussli-Melchers et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: